This podcast might not actually kill you, but it covers so many things that can. Each episode tackles a different disease, from its history, to its biology, and finally, how scared you need to be. Ecologists and epidemiologists Erin Welsh and Erin Allmann Updyke make infectious diseases acceptable fodder for dinner party conversation and provide the perfect cocktail recipe to match.
…
continue reading
Mazyar Shadman, MD, MPH, Peter A. Riedell, MD - Finding Treatment Synergy in CLL: Expert Consults on Advances With Targeted and Cellular Therapy
MP3•Episode home
Manage episode 359203164 series 41876
By PeerView, 24 West 40th Street, Suite 950, New York, NY 10018, PVI, and PeerView Institute for Medical Education. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.
Go online to PeerView.com/AEQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to achieve therapeutic synergy in CLL and leverage the potency of targeted platforms along with emerging cellular therapy options? Find out by watching this “Clinical Consults” event recorded at the 2023 Tandem Meetings, where experts presenting the latest practice-changing evidence provide practical take-homes on the upfront and sequential use of covalent and noncovalent BTK and BCL-2 inhibitors, the emergence of potent chemo-sparing combinatorial approaches, the changed role of HCT, and the development of CAR-T cell options in pretreated CLL. Get CME credit and hear how experts are getting better outcomes through treatment synergy, including in challenging and high-risk CLL settings. Upon completion of this activity, participants should be better able to: Summarize the safety and efficacy evidence and practice guidelines supporting the use of novel BTK and BCL-2 inhibitors, and CAR-T cellular therapy, including as part of novel combinations and sequential approaches, across the spectrum of CLL; Integrate novel targeted and cellular approaches in conjunction with monitoring strategies for the personalized management of patients with TN and RR CLL; and Manage the unique spectrum of adverse events associated with the use of novel therapies in the CLL setting
…
continue reading
1034 episodes